
Bio-Rad Laboratories BIO
$ 320.95
5.1%
Quarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Total Assets 2011-2026 | BIO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.36 B | 12.3 B | 13.5 B | 17.8 B | 13 B | 8.01 B | 5.61 B | 4.27 B | 3.85 B | 3.71 B | 3.34 B | 3.39 B | 3.44 B | 3.1 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.8 B | 3.1 B | 7.48 B |
Quarterly Total Assets Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 B | 9.53 B | 10.6 B | 9.69 B | 12.6 B | 11.9 B | 12 B | 13.7 B | 13.5 B | 12.1 B | - | 14.4 B | 17.8 B | 20 B | 15.1 B | 13.9 B | 13 B | 13 B | 13 B | 13 B | 8.01 B | 8.01 B | 8.01 B | 8.01 B | 5.61 B | 5.61 B | 5.61 B | 5.61 B | 4.27 B | 4.27 B | 4.27 B | 4.27 B | 3.85 B | 3.85 B | 3.85 B | 3.85 B | 3.71 B | 3.71 B | 3.71 B | 3.71 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.39 B | 3.39 B | 3.39 B | 3.39 B | 3.44 B | 3.44 B | 3.44 B | 3.44 B | 3.1 B | 3.1 B | 3.1 B | 3.1 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20 B | 3.1 B | 7.34 B |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
204 M | $ 31.63 | 2.03 % | $ 1.4 B | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 95.41 | 0.76 % | $ 140 B | ||
|
Abiomed
ABMD
|
1.49 B | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
776 M | $ 21.25 | 2.36 % | $ 3.04 B | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.6 | 2.86 % | $ 125 M | ||
|
Cognyte Software Ltd.
CGNT
|
498 M | $ 9.15 | 2.81 % | $ 657 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
2.31 B | $ 42.12 | 3.97 % | $ 1.3 B | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 50.6 | 5.18 % | $ 7.54 K | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.48 | 2.35 % | $ 130 M | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 126.37 | 1.76 % | $ 220 B | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
53.8 M | $ 28.03 | 2.34 % | $ 237 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
786 M | $ 15.27 | 3.18 % | $ 1.21 B | ||
|
IRadimed Corporation
IRMD
|
98.3 M | $ 98.11 | 2.73 % | $ 1.24 B | ||
|
Align Technology
ALGN
|
6.21 B | $ 160.18 | 2.66 % | $ 12 B | ||
|
OrthoPediatrics Corp.
KIDS
|
473 M | $ 18.13 | 3.22 % | $ 418 M | ||
|
Accuray Incorporated
ARAY
|
470 M | $ 0.89 | 4.38 % | $ 91.5 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
39.2 M | $ 14.34 | 2.21 % | $ 388 M | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.52 | 0.03 % | $ 121 M | ||
|
LivaNova PLC
LIVN
|
2.51 B | $ 63.29 | 4.37 % | $ 3.43 B | ||
|
LENSAR
LNSR
|
66.3 M | $ 11.32 | -2.5 % | $ 130 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.21 | 3.42 % | $ 19.5 M | ||
|
Globus Medical
GMED
|
5.25 B | $ 90.81 | 4.02 % | $ 12.3 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 12.56 | 4.58 % | $ 967 M | ||
|
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | ||
|
Establishment Labs Holdings
ESTA
|
347 M | $ 65.25 | -5.21 % | $ 1.84 B |